Daratumumab and Hyaluronidase-fihj Approved For Patients With Myeloma
The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or relapsed/refractory multiple myeloma (MM). Daratumumab was...
Subcutaneous Daratumumab is Noninferior to IV Administration in Relapsed/Refractory Myeloma
Subcutaneous daratumumab was found to be noninferior to intravenous (IV) daratumumab in patients with relapsed or refractory multiple myeloma (MM), according to results from...
Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed Myeloma
Initial treatment with carfilzomib, lenalidomide, and dexamethasone was not associated with greater improvements in progression-free survival compared with bortezomib, lenalidomide, and dexamethasone. Shaji Kumar,...
DREAMM-6: Evaluating Belantamab Mafodotin and Bortezomib Plus Dexamethasone in Relapsed/Refractory Myeloma
Early data from the DREAMM-6 study suggest that the combination of belantamab mafodotin, bortezomib, and dexamethasone is active in patients with relapsed or refractory...
BOSTON: Weekly Combination Therapy Including Selinexor Improved PFS in Relapsed/Refractory Myeloma
Once weekly combination treatment with selinexor, bortezomib, and dexamethasone (SVd) led to an approximately 4-month improvement in progression-free survival (PFS) compared with bortezomib plus...
Predicting Survival in MM With Renal Impairment and Light Chain Cast Nephropathy
The quality of renal response to therapy was associated with survival in patients with multiple myeloma (MM) with renal impairment and light chain cast...
Early Data for Teclistamab Shows Deep Responses in Myeloma
Janssen Pharmaceuticals has reported preliminary results from the first-in-human phase I dose escalation study of teclistamab for patients with relapsed or refractory multiple myeloma....
Isatuximab-irfc Approved for Multiple Myeloma
The FDA has approved the anti-CD38 monoclonal antibody isatuximab-irfc, in combination with pomalidomide and dexamethasone, for adults with multiple myeloma (MM) who have received...
Daratumumab Monotherapy Produces Rapid, Deep Hematologic Responses in Light Chain Amyloidosis
In a study of previously treated patients with systemic light chain amyloidosis (AL), nearly half of patients treated with intravenous (IV) daratumumab experienced at...
FDA Grants Belantamab Mafodotin Priority Review for Myeloma
The FDA granted priority review to the biologics license application of belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma...
Current Issue
July 2020 Volume 6 Issue 8
This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.
